Enter your keywords

Formulary assessment – estradiol/progesterone (Bijuve) for HRT

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]

Formulary assessment – estradiol spray (Lenzetto)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]

Formulary assessment – testosterone 2% gel (Tostran) in post-menopausal women

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]

Insulin aspart Sanofi (Trurapi): Biosimilar Insulin Aspart

Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes […]

Estradiol spray for the treatment of menopausal symptoms

New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. Download the full review below to read more.

Drugs affecting bone metabolism

This report looks at prescribing trends in primary care for Drugs affecting bone metabolism at CCG and STP level with selected substances analysed at presentation level and also explores associations between prescribing and hospital admissions relating to hip fractures. If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net […]

Fast acting insulin lispro for the treatment of diabetes mellitus

Overview New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. Ultra-rapid acting insulin lispro (Lyumjev®▼, Lilly) is a new formulation of insulin lispro with added treprostinil and citrate to produce a more […]

Drugs used in Diabetes

This report looks at prescribing trends in primary care for Drugs used in Diabetes at CCG and STP level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. If you have any queries about the […]

Cardiovascular outcomes associated with SGLT2 inhibitors (update 2)

The sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population at increased risk of cardiovascular events. Recent clinical trials and cohort studies have assessed whether the SGLT2 inhibitors reduce this risk. Download the full review below to read […]